<DOC>
	<DOCNO>NCT02392793</DOCNO>
	<brief_summary>The drug , talazoparib , seem work cancer test tube animal prevent DNA repair damage cell lead death . Investigators know talazoparib combine irinotecan work human . Talazoparib use small number adult child , much yet know . In Arm A study , investigator seek find safe dose irinotecan give talazoparib child young adult . In phase I study , different dose level drug may test . The first 2 3 patient give dose , none bad side-effect , next 2 3 patient give high dose . No temozolomide give Arm A . The experimental drug combination talazoparib irinotecan test hope find treatment may effective recurrent refractory solid tumor . The goal study Arm A : - To determine whether combination talazoparib irinotecan beneficial treatment cancer ; - To learn kind side effect talazoparib cause ; - To learn kind side effect talazoparib combination irinotecan cause ; - To learn biology talazoparib child diagnose solid tumor . The purpose Arm B find safe dos irinotecan temozolomide give talazoparib child young adult solid malignancy.. Talazoparib belong family drug call `` poly ADP ribose polymerase PARP inhibitor . '' Irinotecan temozolomide belong family drug call `` DNA damaging agent . '' There two arm trial , A B . In study , investigator hope irinotecan ( administer Arm A ) irinotecan plus temozolomide ( administered Arm B ) damage DNA cancer cell . Then , talazoparib ( PARP inhibitor ) block repair cancer cell 's damage DNA , cause cancer cell die ( process call `` apoptosis '' ) . There different type cancer find child young adult appear vulnerable combination chemotherapy agent give study . Work carry lab show agent may promise treatment ewing sarcoma , germ cell tumor , wilms tumor , medulloblastoma possibly neuroblastoma .</brief_summary>
	<brief_title>Talazoparib Plus Irinotecan With Without Temozolomide Children With Refractory Recurrent Solid Malignancies</brief_title>
	<detailed_description>In Arm A study , talazoparib administer orally day 1 either twice per day depend dose level enrol participant . Both oral talazoparib intravenous ( IV ) irinotecan administer daily , day 2-6 . Each cycle last 21 day . Once maximum tolerated dos ( MTDs ) talazoparib irinotecan determine , second arm study ( Arm B ) open administer talazoparib , irinotecan temozolomide . Talazoparib give orally , day 1-6 . Intravenous irinotecan oral temozolomide give day 2-6 . The study estimate maximum tolerated dos , describe toxicity therapy , estimate response rate characterize pharmacokinetics combine talazoparib plus irinotecan without temozolomide . This study traditional dose escalation study use standard 3+3 phase I design . In Arm A , six dose level evaluate combination talazoparib irinotecan . Once MTDs Arm A determine , Arm B open evaluate combination talazoparib , irinotecan temozolomide . PRIMARY OBJECTIVES - ARM A - To estimate maximum tolerated dos ( MTDs ) talazoparib ( daily , day 1-6 ) combine irinotecan ( daily , day 2-6 ) give every 21 day child refractory recurrent solid malignancy . - To identify describe dose limit toxicity talazoparib irinotecan administer combination patient refractory recurrent solid malignancy . PRIMARY OBJECTIVES - ARM B - To estimate maximum tolerate dose ( MTD ) temozolomide ( give daily , day 2-6 ) combine talazoparib ( daily , day 1-6 ) irinotecan ( daily , day 2-6 ) give every 21 day child refractory recurrent solid malignancy . - To identify describe dose limit toxicity temozolomide , talazoparib irinotecan administer combination patient refractory recurrent solid malignancy . SECONDARY OBJECTIVES - To estimate response rate , within confines phase I study , talazoparib plus irinotecan talazoparib plus irinotecan temozolomide administer combination pediatric patient refractory recurrent solid malignancy . - To characterize pharmacokinetics talazoparib plus irinotecan talazoparib plus irinotecan temozolomide give combination child refractory recurrent solid malignancy .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients refractory recurrent solid tumor standard therapy eligible . Patients must histologic verification malignancy original diagnosis time relapse . 12 month 25 year time enrollment study . Patients must BSA ≥ 0.42 m^2 time study enrollment due capsule strength ( ) . Patients must either measureable evaluable disease . Life expectancy must least 8 week . Performance status : Karnofsky ≥ 50 patient &gt; 16 year age ; Lansky ≥ 50 patient ≤ 16 year age . Prior therapy : Patients receive prior therapy irinotecanbased temozolomidebased regimen eligible . Patients receive prior therapy PARP inhibitor talazoparib eligible ; however , patient progress PARP inhibitor plus irinotecan regimen eligible . Organ function : Must adequate organ bone marrow function define follow parameter : Patients solid tumor metastatic bone marrow : Peripheral absolute neutrophil count ( ANC ) ≥1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion within 7 day enrollment ) Hemoglobin ≥ 9 g/dL ( without support ) Patients solid tumor metastatic bone marrow eligible study evaluable hematologic toxicity . These patient must know refractory red cell platelet transfusion . At least 2 every cohort 3 patient must evaluable hematologic toxicity . If dose limit hematologic toxicity observe dose level , subsequent patient enrol must evaluable hematologic toxicity . Adequate renal function define : Serum creatinine concentration ≤3x institutional upper limit normal ( ULN ) creatinine clearance radioisotope GFR ≥ 70ml/min/1.73m^2 . Adequate liver function define : For Part A participant : normal liver function define SGPT ( ALT ) concentration ≤5x institutional ULN , total bilirubin concentration ≤2x institutional ULN age , serum albumin ≥ 2g/dL . Adequate liver function define : For Part B participant : normal liver function define SGPT ( ALT ) concentration &lt; 2.5 time institutional ULN , total bilirubin concentration ≤ 1.5 time institutional ULN age , serum albumin ≥ 2 g/dL . Patients must fully recover acute toxic effect chemotherapy , immunotherapy , surgery , radiotherapy prior enter study : Myelosuppressive chemotherapy : Patient receive myelosuppressive chemotherapy within 3 week enrollment onto study ( 6 week prior nitrosourea ) . Hematopoietic growth factor : At least 7 day must elapse since completion therapy growth factor . At least 14 day must elapse receive pegfilgrastim . Biologic ( antineoplastic agent ) : At least 7 day must elapse since completion therapy biologic agent . For agent know adverse event occur beyond 7 day administration , period prior enrollment must extend beyond time adverse event know occur . Monoclonal antibody : At least 3 halflives must elapse since prior therapy include monoclonal antibody . Radiotherapy : At least 2 week must elapse since irradiation ; least 6 week must elapse since craniospinal RT substantial bone marrow irradiation . All patient and/or parent legally authorize representative must sign write informed consent . Assent obtain , appropriate , accord institutional guideline . EXCLUSION CRITERIA : Pregnant breastfeeding . If sexually active childbearing potential , must agree use effective method contraception , intrauterine device , bilateral tubal ligation ≥ 6 month randomization , partner vasectomize ≥ 6 month randomization , sexual abstinence relation prefer usual lifestyle subject . Male subject must use condom sex pregnant woman sex woman childbearing potential time first dose study drug 105 day last dose study drug . Contraception consider nonpregnant female partner childbearing potential . Male subject partner childbearing potential must use condom contraception consider female partner time first dose study drug 105 day last dose study drug . Male subject whose partner pregnant use condom duration pregnancy . Male female subject must agree donate sperm egg , respectively , first dose study drug 105 day 45 day last dose study drug , respectively ( hormonal contraception allow ) prior study entry , treatment , 45 day last dose study drug . Females consider childbearing potential include surgically sterile ( bilateral salpingectomy , bilateral oophorectomy , hysterectomy ) post menopausal , define : &lt; 55 year age spontaneous menses ≥ 12 month randomization postmenopausal follicle stimulate hormone ( FSH ) concentration &gt; 30 IU/L ( meet criterion postmenopausal status local laboratory ) . If female childbearing potential , negative serum pregnancy test Screening willing additional serum urine pregnancy test study Note : Females without childbearing potential include menopause ≥2 year , tubal ligation ≥1 year screening , total hysterectomy . Concomitant medication Corticosteroids : Patients receive corticosteroid stable decrease dose least 7 day prior enrollment eligible . Investigational drug : Patients receive investigational drug study . AntiGVHD drug posttransplant : Patients receive cyclosporine , tacrolimus GVHD agent eligible . Prior treatment talazoparib . Unable swallow capsule . Active , uncontrolled infection . Prior solid organ transplant . Prior total body irradiation ( TBI ) . Unwilling unable comply safety monitoring requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>